Oligonucleotide News and Research

RSS

Antigene therapy uses light energy to silence gene activity: Review article

Antigene therapy is a promising new treatment strategy that uses a DNA-based drug to pinpoint light energy to a target gene shutting down its activity.

22 Oct 2010

Regulus present advancements in microRNA platform at Oligonucleotide Therapeutics Society meeting

Regulus Therapeutics Inc. announced today that advancements from its leading microRNA platform and product pipeline were presented at the "6th Annual Meeting of the Oligonucleotide Therapeutics Society" held October 20 - 23, 2010 in Dana Point, California.

22 Oct 2010

Idera announces IMO-3100 Phase 1 clinical trial results for autoimmune disease

Idera Pharmaceuticals, Inc. today announced results from its single-dose, dose-escalation Phase 1 clinical trial evaluating the safety and mechanism of action of IMO-3100, its lead Toll-like Receptor (TLR) 7 and TLR9 antagonist drug candidate for the treatment of autoimmune and inflammatory diseases.

22 Oct 2010

Bioniche's research scientists give presentations at Modern Vaccine and Adjuvant Formulation Conference

Bioniche Life Sciences Inc. a research-based, technology driven Canadian biopharmaceutical company, today announced that two of its senior research scientists gave presentations at the Modern Vaccine and Adjuvant Formulation Conference in Cannes, France this week.

18 Oct 2010

Prosensa receives £7.5M milestone payment in GSK2402968 Phase IIa trial for DMD

Prosensa, the Dutch biopharmaceutical company focusing on RNA modulating therapeutics, has announced that it received a £7.5m milestone payment from GlaxoSmithKline (GSK) as a result of achieving a data milestone in its Phase IIa open label extension trial of GSK2402968 (PRO051), being developed to treat Duchenne Muscular Dystrophy (DMD) under its agreement with GSK. The milestone payment was based upon achievement of a successful safety review, with no serious safety signals observed.

13 Oct 2010

Alnylam Pharmaceuticals to present results on RNAi therapeutics at ACS National Meeting

Alnylam Pharmaceuticals, Inc.,a leading RNAi therapeutics company, announced today that it will make a total of 16 oral presentations at the American Chemical Society (ACS) Fall 2010 240th National Meeting & Exposition being held in Boston, Mass. from August 22-26, 2010.

24 Aug 2010

Rxi Pharmaceuticals second-quarter net loss decreases to $2.1 million

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today reported its financial results for the second quarter ended June 30, 2010.

11 Aug 2010

Alnylam second-quarter revenues increase to $26.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2010, and company highlights.

5 Aug 2010

Bio-Path commences dosing in Liposomal Grb-2 Phase I cancer study

Bio-Path Holdings, Inc.,, a biotechnology company with drug development operations in Houston, Texas, announced today that the first patient has been dosed in a Phase I study of its cancer drug candidate, Liposomal Grb-2 (L-Grb-2 or BP-100-1.01), in patients with Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL) or Myelodysplastic Syndrome (MDS).

30 Jul 2010

Affymetrix launches QuantiGene ViewRNA Assay formats

Affymetrix, Inc. today announced the launch of QuantiGene® ViewRNA Assay formats, which enable a new era of "in situ multiplex gene expression analysis" by allowing drug screening of native cells and advancing the pace of biomarker disease research and stem cell studies. These in situ assays enable researchers to visualize gene expression in individual cells at an unprecedented level of sensitivity and speed.

22 Jul 2010

TriLink, Affymetrix sign distribution and supply agreement

TriLink BioTechnologies, Inc. today announced that a multi-year distribution and supply agreement has been signed with California-based Affymetrix, Inc., a leading supplier of genetic analysis technologies. Under the terms of agreement, Affymetrix will use TriLink's high quality oligonucleotides in several of their kits.

19 Jul 2010

Nitto Denko, Quark collaborate to develop siRNA therapeutics for fibrotic diseases

Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.

15 Jul 2010

CSHL scientists reverse symptoms of Type III SMA using ASOs

The devastating, currently incurable motor-neuron disease spinal muscular atrophy might soon be treated with tiny, chemically modified pieces of RNA called antisense oligonucleotides.

13 Jul 2010

Idera announces issuance of patents for synthetic immune modulatory oligonucleotides targeted to TLRs

Idera Pharmaceuticals, Inc. today announced the issuance of patents covering compositions and methods of using its synthetic immune modulatory oligonucleotides targeted to Toll-like receptors (TLRs). The Company's intellectual property portfolio currently contains over 500 patents and patent applications worldwide and includes claims for TLR-targeted compounds, second-generation antisense chemistry, and oral delivery of certain oligonucleotides.

8 Jul 2010

Advanced Cancer Therapeutics secures $10M in investments

Advanced Cancer Therapeutics (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, today announced that it has secured $10 million in investments from high net-worth individuals and institutions. This round of investment, which closed six months ahead of the company's year-end goal, will provide ACT additional capital to continue its development and commercialization of potentially lifesaving therapeutics for cancer patients.

2 Jul 2010

Bioniche announces issuance of new patents for MCC, Oligonucleotide technology platforms

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced the issuance of a number of patents for its proprietary Mycobacterial Cell Wall-DNA Complex (MCC) composition and its Oligonucleotide technology platform.

18 Jun 2010

Alnylam, Mount Sinai scientists discover svRNAs that play a critical role in influenza A virus replication

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the publication of new research findings in the journal Proceedings of the National Academy of Sciences (PNAS) by Alnylam scientists and collaborators from Mount Sinai School of Medicine. In the new study, Alnylam and Mount Sinai scientists discovered a novel class of virus-produced small non-coding RNAs, called small viral RNAs (svRNAs), which play a critical role in the replication of influenza A virus.

2 Jun 2010

Regulus Therapeutics obtains rights to intellectual property covering methods for modulating microRNA-21

Regulus Therapeutics Inc. announced today that it has obtained exclusive rights from the University of Wuerzburg to intellectual property covering methods for modulating microRNA-21. Regulus scientists and collaborators have shown that microRNA-21, (miR-21), is dysregulated in mouse models of cardiac disease and fibrosis, and that antagonizing miR-21 with therapeutic oligonucleotides targeting miR-21 inhibits fibrosis and attenuates cardiac function in such models. Regulus is currently developing a microRNA therapeutic targeting miR-21 as an anti-fibrotic therapy.

28 May 2010

NOXXON Pharma closes €33 million Series D round of financing

NOXXON Pharma AG, a company focused on the development of mirror image oligonucleotide therapeutics called Spiegelmers®, announced today the successful closing of a €33 million Series D round of financing. The round was led by new investor, NGN Capital, and joined by existing investors TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Seventure Partners, VC Fonds Technologie Berlin GmbH, Dow Venture Capital, FCP OP MEDICAL BioHealth-Trends, IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH, the Dieckell Group, and others.

27 May 2010

Genzyme to initiate $2 billion stock buyback

Genzyme Corp. today announced that its Board of Directors has voted to pursue several actions to increase shareholder value. The company will initiate a $2 billion stock buyback, under which $1 billion of stock will be repurchased in the near term and financed with debt. The additional $1 billion of stock will be repurchased during the next 12 months.

7 May 2010

Oligonucleotide News and Research

Antigene therapy uses light energy to silence gene activity: Review article

Regulus present advancements in microRNA platform at Oligonucleotide Therapeutics Society meeting

Idera announces IMO-3100 Phase 1 clinical trial results for autoimmune disease

Bioniche's research scientists give presentations at Modern Vaccine and Adjuvant Formulation Conference

Prosensa receives £7.5M milestone payment in GSK2402968 Phase IIa trial for DMD

Alnylam Pharmaceuticals to present results on RNAi therapeutics at ACS National Meeting

Rxi Pharmaceuticals second-quarter net loss decreases to $2.1 million

Alnylam second-quarter revenues increase to $26.6 million

Bio-Path commences dosing in Liposomal Grb-2 Phase I cancer study

Affymetrix launches QuantiGene ViewRNA Assay formats

TriLink, Affymetrix sign distribution and supply agreement

Nitto Denko, Quark collaborate to develop siRNA therapeutics for fibrotic diseases

CSHL scientists reverse symptoms of Type III SMA using ASOs

Idera announces issuance of patents for synthetic immune modulatory oligonucleotides targeted to TLRs

Advanced Cancer Therapeutics secures $10M in investments

Bioniche announces issuance of new patents for MCC, Oligonucleotide technology platforms

Alnylam, Mount Sinai scientists discover svRNAs that play a critical role in influenza A virus replication

Regulus Therapeutics obtains rights to intellectual property covering methods for modulating microRNA-21

NOXXON Pharma closes €33 million Series D round of financing

Genzyme to initiate $2 billion stock buyback

Industry Focus eBook - Protein Analysis (3rd edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News